Maximus (NYSE:MMS) Cut to Hold at Wall Street Zen

Maximus (NYSE:MMS) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities analysts have also recently issued reports on MMS. Zacks Research raised shares of Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Maximus in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat.com, the company has an average rating of “Strong Buy”.

Maximus Price Performance

Maximus stock opened at $75.17 on Friday. The stock has a market capitalization of $4.10 billion, a price-to-earnings ratio of 11.44 and a beta of 0.57. Maximus has a 52-week low of $63.77 and a 52-week high of $100.00. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.64 and a current ratio of 2.34. The stock’s 50 day moving average price is $90.07 and its two-hundred day moving average price is $86.38.

Maximus (NYSE:MMS) last released its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. Maximus’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.61 EPS. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, equities analysts predict that Maximus will post 6.15 earnings per share for the current year.

Insider Buying and Selling at Maximus

In related news, insider Michelle F. Link sold 4,039 shares of Maximus stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $86.84, for a total transaction of $350,746.76. Following the transaction, the insider owned 19,542 shares of the company’s stock, valued at $1,697,027.28. The trade was a 17.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maximus

Large investors have recently bought and sold shares of the stock. LSV Asset Management grew its stake in shares of Maximus by 35.5% in the 4th quarter. LSV Asset Management now owns 163,600 shares of the health services provider’s stock worth $14,122,000 after acquiring an additional 42,900 shares in the last quarter. Kingdom Financial Group LLC. purchased a new position in Maximus during the fourth quarter worth about $141,000. PNC Financial Services Group Inc. boosted its holdings in Maximus by 84.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,751 shares of the health services provider’s stock worth $583,000 after purchasing an additional 3,085 shares during the last quarter. ProShare Advisors LLC grew its position in Maximus by 4.4% in the 4th quarter. ProShare Advisors LLC now owns 12,617 shares of the health services provider’s stock worth $1,089,000 after purchasing an additional 537 shares in the last quarter. Finally, HighTower Advisors LLC increased its stake in Maximus by 14.7% in the 4th quarter. HighTower Advisors LLC now owns 6,431 shares of the health services provider’s stock valued at $555,000 after buying an additional 823 shares during the last quarter. 97.21% of the stock is currently owned by institutional investors.

Maximus News Roundup

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Q1 EPS narrowly beat expectations — Maximus reported $1.85 EPS vs. the $1.84 consensus, showing earnings strength and year‑over‑year EPS improvement. Maximus (MMS) Q1 Earnings Top Estimates
• Positive Sentiment: Margins improved — management emphasized margin gains and cost discipline during the call, which supports near‑term profitability despite revenue pressure. Maximus Earnings Call: Margins Rise Amid Revenue Pressure
• Neutral Sentiment: Full disclosure and investor materials posted — the company released the press release, slide deck and earnings‑call transcript for detailed review (useful for modeling/QA but not market moving by itself). View Press Release / Slide Deck
• Negative Sentiment: Revenue miss and YoY decline — Q1 revenue was $1.35B vs. ~$1.37B expected and fell ~4.1% year‑over‑year, signaling near‑term top‑line weakness. Maximus Q1 results and materials
• Negative Sentiment: Tightened / lower FY‑2026 revenue guidance — management set FY‑2026 revenue of $5.2B–$5.4B (below Street ~ $5.5B) and EPS guidance of $8.05–$8.35 (around but slightly below consensus midpoint), which pressured growth expectations. Maximus tops Q1 earnings forecasts while tightening 2026 revenue guidance

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.